Clinical Trial Update: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pinatuzumab vedotin or polatuzumab vedotin in combination with rituximab or obinutuzumab for relapsed/refractory B-cell non-Hodgkin's…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Pinatuzumab Vedotin (DCDT2980S) (pinatuzumab vedotin)
• Polatuzumab Vedotin (DCDS4501A) (polatuzumab vedotin)
• Rituximab (rituximab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Follicular Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-04-19